Neuroimmune Dysregulation and Neuroinflammation in Alzheimer’s Disease and Related Dementias (ADRD) and Neurodegeneration – ZRG1 AN-Z 55
NOTE: Ends after the May 2026 Council round submission dates (ends after Spring 2026 review meetings). This study section was evaluated as part of CSR’s ENQUIRE process which functions to align study sections with advances in science. Learn more about ENQUIRE.
The ZRG1 AN-Z (55) special emphasis panel reviews applications studying aspects of neuroimmune function and neuroinflammation involved in the pathogenesis, pathophysiology, progression, prognosis, biomarkers, and treatment of Alzheimer’s disease and related dementia (ADRD), such as Parkinson’s dementia, Lewy body dementia (LBD), frontotemporal degeneration (FTD) and multi-etiology dementias, aging associated brain functional decline, and other neurodegenerative diseases such as Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS). Studies reviewed by ZRG1 AN-Z (55) employ integrated experimental approaches focusing on preclinical studies but may include studies combining in vitro cellular mechanistic tests and in vivo tests. These studies typically use vertebrate and invertebrate animals, but the panel can also review applications using a combination of animal and human tissues.
Review Dates
Topics
- Involvement and role of microglia activation and neuroinflammation in ADRD and neurodegeneration.
- Involvement other forms of systemic innate immune dysregulations in ADRD and neurodegeneration.
- Involvement of the adaptive immune system, including activation and dysregulation of T cells, B cells, cytokines, and chemokines in ADRD and neurodegeneration.
- Abeta immunotherapy-induced amyloid related imaging abnormalities (ARIA).
- Inflammatory biomarkers.
- Therapeutical development targeting neuroimmune and neuroinflammation mechanisms and pathways.
